<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        364-212-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETAM 500 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        109.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACTAVIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACTAVIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LEVETAM 500 mg film-coated tablets are an antiepileptic medicine (a medicine used to treat&nbsp;<br />seizures in epilepsy).<br />&nbsp;<br />LEVETAM is used:<br />&nbsp;<br />As monotherapy:<br />&nbsp;<br />&bull; in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat&nbsp;<br />partial onset seizures with or without secondary generalisation (a secondary generalisation is&nbsp;<br />when the seizure spreads within the brain).<br />&nbsp;<br />As an add-on to other antiepileptic medicines to treat:<br />&nbsp;<br />&nbsp;&bull; partial onset seizures with or without generalisation in adults, adolescents,&nbsp;<br />children and infants from one month of age<br />&nbsp;<br />&nbsp;&bull; myoclonic seizures in adults and adolescents from 12 years of age with juvenile&nbsp;<br />myoclonic epilepsy</p><p>&nbsp;&bull; primary generalised tonic-clonic seizures in adults and adolescents from 12 years&nbsp;<br />of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic&nbsp;<br />cause)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take LEVETAM<br />&nbsp;<br />&bull; If you are allergic (hypersensitive) to levetiracetam or any of the other ingredients of this&nbsp;<br />medicine (listed in Section 6).<br />&nbsp;<br />Take special care with LEVETAM<br />&nbsp;<br />&nbsp;<br />Talk to your doctor before taking LEVETAM<br />&nbsp;<br />&bull; If you suffer from kidney problems, follow your doctor&rsquo;s instructions. He/she may decide&nbsp;<br />if your dose should be adjusted.<br />&nbsp;<br />&bull; If you notice any slow down in the growth or unexpected puberty development of your&nbsp;<br />child, please contact your doctor.<br />&nbsp;<br />&bull; If you notice an increase in seizure severity (e.g. increased number), please contact your&nbsp;<br />doctor.<br />&nbsp;<br />&bull; A small number of people being treated with anti-epileptics such as LEVETAM have had&nbsp;<br />thoughts of harming or killing themselves. If you have any symptoms of depression and/or&nbsp;<br />suicidal ideation, please contact your doctor.<br />&nbsp;<br />Taking other medicines<br />&nbsp;<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other&nbsp;<br />medicines, including medicines obtained without a prescription.<br />&nbsp;<br />Taking LEVETAM with food, drink and alcohol<br />&nbsp;<br />You may take LEVETAM with or without food. As a safety precaution, do not take LEVETAM&nbsp;<br />with alcohol.<br />&nbsp;<br />Pregnancy and breast-feeding<br />&nbsp;<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />&nbsp;<br />If you are pregnant or if you think you may be pregnant, please inform your doctor.<br />&nbsp;<br />LEVETAM should not be used during pregnancy unless clearly necessary. The potential risk to&nbsp;<br />your unborn child is unknown. Levetiracetam has shown unwanted reproductive effects in&nbsp;<br />animal studies at dose levels higher than you would need to control your seizures.<br />&nbsp;<br />Breast-feeding is not recommended during treatment.<br />&nbsp;<br />Driving and using machines<br />&nbsp;<br />LEVETAM may impair your ability to drive or operate any tools or machinery, as LEVETAM&nbsp;<br />may make you feel sleepy. This is more likely at the beginning of treatment or after an increase&nbsp;<br />in the dose. You should not drive or use machines until it is established that your ability to&nbsp;<br />perform such activities is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your&nbsp;<br />doctor or pharmacist if you are not sure.<br />&nbsp;<br />LEVETAM must be taken twice a day, once in the morning and once in the evening, at about the&nbsp;<br />same time each day.<br />&nbsp;<br />Take the number of tablets following your doctoracutes instructions.<br />&nbsp;<br />Monotherapy<br />&nbsp;<br />Dose in adults and adolescents (from 16 years of age):<br />&nbsp;<br />General dose: between 1,000 mg (2 tablets) and 3,000 mg (6 tablets) each day.<br />&nbsp;<br />When you will first start taking LEVETAM, your doctor will prescribe you a lower dose during&nbsp;<br />2 weeks before giving you the lowest general dose.<br />&nbsp;<br />Example: if your daily dose is 2,000 mg, you must take 2 tablets in the morning and 2 tablets in&nbsp;<br />the evening.<br />&nbsp;<br />Add-on therapy<br />&nbsp;<br />Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more:<br />&nbsp;<br />General dose: between 1,000 mg (2 tablets) and 3,000 mg (6 tablets) each day.<br />&nbsp;<br />Example: if your daily dose is 1,000 mg, you must take one tablet in the morning and one tablet&nbsp;<br />in the evening.<br />&nbsp;<br />&nbsp;<br />Dose in infants (6 to 23 months), children (2 to 11 years) and adolescents (12 to 17 years)&nbsp;<br />weighing less than 50 kg:<br />&nbsp;<br />Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according&nbsp;<br />to the age, weight and dose.<br />&nbsp;<br />An oral solution is a presentation more appropriate to infants and children under the age of 6&nbsp;<br />years.<br />&nbsp;<br />General dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day.&nbsp;<br />&nbsp;<br />Example: a general dose of 20 mg per kg bodyweight each day, you must give your 25 kg child&nbsp;<br />1 tablet in the morning and 1 tablet in the evening.<br />&nbsp;<br />Dose in infants (1 month to less than 6 months):<br />&nbsp;<br />An oral solution is a presentation more appropriate to infants.&nbsp;<br />&nbsp;<br />Method of administration<br />&nbsp;<br />Swallow LEVETAM tablets with a sufficient quantity of liquid (e.g. a glass of water).<br />&nbsp;<br />Duration of treatment<br />&nbsp;<br />&bull; LEVETAM is used as a chronic treatment. You should continue LEVETAM treatment&nbsp;<br />for as long as your doctor has told you.<br />&nbsp;<br />&bull; Do not stop your treatment without your doctor&rsquo;s advice as this could increase your&nbsp;<br />seizures.<br />&nbsp;<br />&nbsp;Should your doctor decide to stop your LEVETAM treatment, he/she will instruct you&nbsp;<br />about the gradual withdrawal of LEVETAM.<br />&nbsp;<br />If you take more LEVETAM than you should<br />&nbsp;<br />The possible side effects of an overdose of levetiracetam are sleepiness, agitation, aggression,&nbsp;<br />decrease of alertness, inhibition of breathing and coma.<br />&nbsp;<br />Contact your doctor if you took more tablets than you should. Your doctor will establish the best&nbsp;<br />possible treatment of overdose.<br />&nbsp;<br />If you forget to take LEVETAM<br />&nbsp;<br />Contact your doctor if you have missed one or more doses.<br />&nbsp;<br />Do not take a double dose to make up for a forgotten tablet.<br />&nbsp;<br />&nbsp;<br />If you stop taking LEVETAM<br />&nbsp;<br />If stopping treatment, as with other antiepileptic medicines, LEVETAM should be discontinued&nbsp;<br />gradually to avoid an increase of seizures.<br />&nbsp;<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />&nbsp;<br />Some of the side effects like sleepiness, tiredness and dizziness may be more common at the&nbsp;<br />beginning of the treatment or at dose increase. These effects should however decrease over time.<br />&nbsp;<br />Very common: may affect more than 1 user in 10<br />&nbsp;<br />&bull; nasopharyngitis;<br />&nbsp;<br />&bull; somnolence (sleepiness), headache.<br />&nbsp;<br />Common: may affect 1 to 10 users in 100<br />&nbsp;<br />&bull; anorexia (loss of appetite);<br />&nbsp;<br />&bull; depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;<br />&nbsp;<br />&bull; convulsion, balance disorder (equilibrium disorder), dizziness (sensation of&nbsp;<br />unsteadiness), lethargy, tremor (involuntary trembling);<br />&nbsp;<br />&bull; vertigo (sensation of rotation);<br />&nbsp;<br />&bull; cough;<br />&nbsp;<br />&bull; abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;<br />&nbsp;<br />&bull; rash;<br />&nbsp;<br />&bull; asthenia/fatigue (tiredness).<br />&nbsp;<br />Uncommon: may affect 1 to 10 users in 1000<br />&nbsp;<br />&bull; decreased number of blood platelets, decreased number of white blood cells;&nbsp;<br />&nbsp;<br />&bull; weight decrease, weight increase;<br />&nbsp;<br />&bull; suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination,&nbsp;<br />anger, confusion, panic attack, emotional instability/mood swings, agitation;<br />&nbsp;<br />&bull; amnesia (loss of memory), memory impairment (forgetfulness), abnormal&nbsp;<br />coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in&nbsp;<br />attention (loss of concentration);<br />&nbsp;<br />&bull; diplopia (double vision), vision blurred;<br />&nbsp;<br />&bull; liver function test abnormal;<br />&nbsp;<br />&bull; hair loss, eczema, pruritus;&nbsp;<br />&nbsp;<br />&bull; muscle weakness, myalgia (muscle pain);<br />&nbsp;<br />&bull; injury.<br />&nbsp;<br />Rare: may affect 1 to 10 users in 10,000<br />&nbsp;<br />&bull; infection;<br />&nbsp;<br />&bull; decreased number of all blood cell types;&nbsp;<br />&nbsp;<br />&bull; suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking,&nbsp;<br />unable to concentrate);<br />&nbsp;<br />&bull; uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling&nbsp;<br />movements, hyperkinesia (hyperactivity);<br />&nbsp;<br />&bull; pancreatitis;<br />&nbsp;<br />&bull; hepatic failure, hepatitis;<br />&nbsp;<br />&bull; &nbsp;skin rash, which may form blisters and looks like small targets (central dark spots&nbsp;<br />surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a&nbsp;<br />widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and&nbsp;<br />genitals (Stevens&ndash;Johnson syndrome), and a more severe form causing skin peeling in more than&nbsp;<br />30% of the body surface (toxic epidermal necrolysis).<br />&nbsp;<br />If you get any side effects talk to your doctor or pharmacist. This includes any possible side&nbsp;<br />effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />&nbsp;<br />Do not use this medicine after the expiry date stated on the carton after EXP. The expiry date&nbsp;<br />refers to the last day of the month.<br />&nbsp;<br />This medicinal product does not require any special storage conditions.&nbsp;<br />Do not store above 30&deg; C.&nbsp;<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how&nbsp;<br />to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;The active substance is levetiracetam.&nbsp;<br />&nbsp;<br />Each film-coated tablet contains 500 mg levetiracetam.<br />&nbsp;<br />- The other ingredients are: Crospovidon, povidone, silica colloidal anhydrous, magnesium&nbsp;<br />stearate, polyvinyl alcohol&ndash;part. hydrolyzed, macrogol 4000, talc, titanium dioxide (E171), Iron&nbsp;<br />oxide yellow (E172), Indigo carmine (E132).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Film-coated tablet.
 
Yellow  color oval, biconvex, film-coated tablet, debossed with "105" on one side and plain on 
the other side. 
Each Pack contains 30 film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO&nbsp;<br />Al-Qassim Pharmaceutical Plant&nbsp;<br />Saudi Pharmaceutical Industries &amp;&nbsp;<br />Medical Appliances Corporation&nbsp;<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ليفيتام 500 ملجم أقراص مغلفة بطبقة رقيقة هي دواء مضاد للصرع (دواء يستخدم لعلاج نوبات الصرع)&nbsp;</p><p>يستخدم&nbsp; ليفيتام فى&nbsp;:&nbsp;</p><p>كعلاج وحيد:&nbsp;</p><ul><li><p>في البالغين والمراهقين من سن 16 سنة المصابين بالصرع الذى تم تشخيصه حديثا، لعلاج النوبات الجزئية مع أو بدون تعميم ثانوي (التعميم الثانوي هو عندما تنتشر النوبات داخل المخ).&nbsp;</p></li></ul><p>كإضافة على الأدوية المضادة للصرع الأخرى لعلاج:&nbsp;</p><ul><li><p>النوبات الجزئية مع أو بدون تعميم ثانوي فى البالغين والمراهقين و الأطفال من سن شهر واحد.&nbsp;</p></li><li><p>نوبات الرمع العضلي لدى البالغين والمراهقين من سن 12 سنة و المصابين بصرع الرمع العضلي للأحداث.&nbsp;</p></li><li><p>نوبات الأولية المعممة التوترية الإرتجاجية في البالغين والمراهقين من سن 12 سنة المصابين بالصرع المعمم مجهول السبب (نوع من الصرع التي يعتقد أن يكون لها سبب وراثي)&nbsp;</p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول ليفيتام&nbsp;</p><p>إذا كنت تعاني من حساسية (فرط الحساسية) لـ ليفيتيراسيتام أو أي من المكونات الأخرى في هذا الدواء (المدرجة في القسم 6).&nbsp;</p><p>&nbsp;</p><p>ينبغى توخى الحذر مع ليفيتام&nbsp;</p><p>&nbsp;</p><p>تحدث إلى طبيبك قبل تناول ليفيتام&nbsp;</p><p>&nbsp;</p><ul><li><p>إذا كنت تعاني من مشاكل في الكلى، اتبع تعليمات الطبيب. انه / انها قد تقرر ما إذا كان ينبغي تعديل الجرعة.&nbsp;</p></li></ul><ul><li><p>إذا لاحظت أي تباطؤ غير متوقع في نمو أو تطور فترة البلوغ لطفلك، يرجى الاتصال بالطبيب.&nbsp;</p></li><li><p>إذا لاحظت زيادة في شدة النوبات (على سبيل المثال زيادة العدد)، يرجى الاتصال بالطبيب.&nbsp;</p></li><li><p>كان هناك عدد قليل من الأشخاص الذين يعالجون مع مضادات الصرع مثل ليفيتام لديهم أفكار إيذاء أو قتل أنفسهم. إذا كان لديك أي أعراض الإكتئاب و / أو التفكير في الإنتحار، يرجى الاتصال بالطبيب.&nbsp;</p></li></ul><p>&nbsp;</p><p>تناول أدوية أخرى&nbsp;</p><p>يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.&nbsp;</p><p>&nbsp;</p><p>تناول ليفيتام مع الطعام والشراب و الكحول&nbsp;</p><p>قد تتناول ليفيتام مع أو بدون الطعام. كإجراء احترازي، لا تأخذ ليفيتام مع الكحول.&nbsp;</p><p>الحمل و الرضاعة&nbsp;</p><p>إسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.&nbsp;</p><p>إذا كنت حاملا أو إذا كنت تعتقدين أنك قد تكوني حاملا، الرجاء إبلاغ الطبيب.&nbsp;</p><p>لا ينبغي أن تستخدمى ليفيتام أثناء الحمل إلا عند الضرورة بشكل واضح. الخطر المحتمل على الطفل الذي لم يولد بعد غيرمعروف. وقد أظهر ليفيتام في الدراسات على الحيوانات آثار إنجابية غير مرغوب فيها عند جرعات أعلى مما قد تحتاجين للسيطرة على النوبات الخاص بك.&nbsp;</p><p>لا ينصح الرضاعة الطبيعية أثناء العلاج.&nbsp;</p><p>القيادة و استخدام الآلات&nbsp;</p><p>قد يضعف ليفيتام قدرتك على القيادة أو تشغيل أي أدوات أو آلات، قد يجعلك ليفيتام تشعر بالنعاس. هذا هو الأرجح في بداية العلاج أو بعد زيادة في الجرعة. يجب أن لا تقود أو تستخدم الآلات حتى يثبت أن قدرتك على أداء مثل هذه الأنشطة لا يتأثر.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.&nbsp;</p><p>يجب أن يؤخذ ليفيتام مرتين في اليوم، مرة في الصباح ومرة في المساء، في الوقت نفسه تقريبا كل يوم.&nbsp;</p><p>تناول عدد الأقراص الذى يحدده لك الطبيب.&nbsp;</p><p>كعلاج وحيد&nbsp;</p><p>الجرعة في البالغين والمراهقين (من سن 16 سنة):&nbsp;</p><p>الجرعة العامة: بين 1,000&nbsp; ملجم (قرصين) و 3,000 ملجم&nbsp; (6 أقراص) كل يوم.&nbsp;</p><p>عندما تبدأ تناول ليفيتام لأول مرة، سوف يصف لك طبيبك أقل جرعة خلال أسبوعين قبل إعطائك أقل جرعة عامة.&nbsp;</p><p>مثال: إذا الجرعة اليومية هو 2,000&nbsp; ملجم ، يجب أن تأخذ 2 قرص في الصباح و2 قرص في المساء.&nbsp;</p><p>إضافة على علاج&nbsp;</p><p>الجرعة في البالغين والمراهقين (12-17 سنة) وزن 50 كجم أو أكثر:&nbsp;</p><p>الجرعة العامة: بين 1,000&nbsp; ملجم (قرصين) و 3,000 ملجم&nbsp; (6 أقراص) كل يوم.&nbsp;</p><p>مثال: إذا الجرعة اليومية هو 1,000&nbsp; ملجم ، يجب أن تأخذ&nbsp; قرص في الصباح و قرص في المساء.&nbsp;</p><p>الجرعة عند الرضع ( 6 - 23&nbsp; شهرا) والأطفال ( 2 - 11 سنة) والمراهقين ( 12 - 17 سنة) وزن أقل من 50 كجم:&nbsp;</p><p>طبيبك سوف يصف الشكل الدوائى الأكثر ملاءمة من ليفيتيراسيتام وفقا للعمر والوزن والجرعة.&nbsp;</p><p>المحلول عن طريق الفم هو أكثر ملاءمة للرضع والأطفال الذين تقل أعمارهم عن 6 سنوات.&nbsp;</p><p>الجرعة العامة: بين 20 ملجم لكل كيلو جرام من وزن الجسم، و 60 ملجم لكل كيلو جرام من وزن الجسم كل يوم.&nbsp;</p><p>مثال: الجرعة العامة للـ 20 ملجم لكل كيلو جرام من وزن الجسم كل يوم، يجب أن تعطي طفلك الذى يزن 25 كجم 1 قرص في الصباح و 1 قرص في المساء.&nbsp;</p><p>الجرعة عند الرضع (1 شهر إلى أقل من 6 أشهر):&nbsp;</p><p>المحلول عن طريق الفم هو أكثر ملاءمة للرضع.&nbsp;</p><p>طريقة التناول:&nbsp;</p><p>ابتلاع أقراص ليفيتام مع كمية كافية من السوائل (مثل كوب من الماء).&nbsp;</p><p>مدة العلاج&nbsp;</p><p>&bull; يستخدم ليفيتام كعلاج مزمن. يجب أن يستمر العلاج ليفيتام طالما أخبرك طبيبك.&nbsp;</p><p>&bull; لا تتوقف عن العلاج دون استشارة الطبيب لأن ذلك قد يزيد النوبات الخاصة بك.&nbsp;</p><p>إذا قرر طبيبك وقف العلاج بـ ليفيتام ، فإنه سوف يقوم بسحب تدريجي لـ ليفيتام.&nbsp;</p><p>إذا تتناولت ليفيتام أكثر مما يجب&nbsp;&nbsp;</p><p>الآثار الجانبية المحتملة للجرعة الزائدة من ليفيتيراسيتام هي النعاس، والتهيج، والعدوان، وانخفاض اليقظة، وتثبيط التنفس والغيبوبة.&nbsp;</p><p>اتصل بطبيبك إذا أخذت أقراص أكثر مما يجب. طبيبك سوف ينشئ أفضل علاج ممكن للجرعة الزائدة.&nbsp;</p><p>إذا نسيت أن تأخذ ليفيتام&nbsp;</p><p>اتصل بطبيبك إذا كنت قد نسيت جرعة أو أكثر.&nbsp;</p><p>لا تأخذ جرعة مضاعفة لتعويض القرص المنسي.&nbsp;</p><p>إذا توقفت عن تناول ليفيتام&nbsp;</p><p>إذا وقفت العلاج، كما هو الحال مع الأدوية المضادة للصرع أخرى، ينبغي وقف ليفيتام تدريجيا لتجنب زيادة النوبات.&nbsp;</p><p>إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، وإن لم تكن تحدث للجميع.&nbsp;</p><p>بعض الآثار الجانبية مثل النعاس والتعب والدوخة قد تكون أكثر شيوعا في بداية العلاج أو عند زيادة الجرعة. ولكن هذه الآثار قد تقل بمرور الوقت.&nbsp;</p><p>شائعة جدا:&nbsp;قد تؤثر فى أكثر من 1 مستخدم من 10:&nbsp;</p><p>&bull; التهاب البلعوم الأنفي؛&nbsp;</p><p>&bull; النعاس والصداع.&nbsp;</p><p>شائعة:&nbsp;قد تؤثر فى 1 إلي 10 مستخدمين من 100:&nbsp;</p><p>&bull; فقدان الشهية (فقدان الشهية)؛&nbsp;</p><p>&bull; الاكتئاب أو العداوة أو العدوان، والقلق، والأرق، والعصبية أو التهيج؛&nbsp;</p><p>&bull; التشنج، واضطراب التوازن (اضطراب التوازن)، والدوخة (الإحساس بعدم الثبات)، والخمول، ورعاش (ارتعاش لاإرادي)؛&nbsp;</p><p>&bull; الدوار (الإحساس بالدوران)؛&nbsp;</p><p>&bull; السعال؛&nbsp;</p><p>&bull; ألم في البطن، والإسهال، وعسر الهضم (عسر الهضم)، والتقيؤ والغثيان؛&nbsp;</p><p>&bull; طفح جلدي؛&nbsp;</p><p>&bull; الوهن / التعب (التعب).&nbsp;</p><p>غير شائعة:&nbsp;قد تؤثر فى1 إلي 10 مستخدمين من 1,000:&nbsp;</p><p>&bull; انخفاض عدد الصفائح الدموية، وانخفاض عدد خلايا الدم البيضاء؛&nbsp;</p><p>&bull; انخفاض الوزن، وزيادة الوزن؛&nbsp;</p><p>&bull; محاولة الانتحار والتفكير في الانتحار، واضطرابات عقلية، والسلوك الشاذ، هلوسة، والغضب، والارتباك، نوبة الهلع، وتقلب المزاج / عدم استقرار عاطفي&nbsp; ، والتهيج؛&nbsp;</p><p>&bull; فقدان الذاكرة (فقدان الذاكرة)، ضعف الذاكرة (النسيان)، و التنسيق الشاذ / ترنح (ضعف فى الحركات المنسقة)، وخز ، اضطراب في الانتباه (فقدان التركيز)؛&nbsp;</p><p>&bull; ازدواج الرؤية (الرؤية المزدوجة)، عدم وضوح الرؤية؛&nbsp;</p><p>&bull; اختلال فى اختبار وظيفة الكبد ؛&nbsp;</p><p>&bull; فقدان الشعر، الأكزيما، حكة؛&nbsp;</p><p>&bull; ضعف العضلات، وألم عضلي (ألم في العضلات)؛&nbsp;</p><p>&bull; الإصابة.&nbsp;</p><p>نادرة:&nbsp;قد تؤثر فى 1 إلي 10 مستخدمين من 10,000:&nbsp;</p><p>&bull; العدوى؛&nbsp;</p><p>&bull; انخفاض عدد جميع أنواع الخلايا في الدم؛&nbsp;</p><p>&bull; الانتحار، اضطرابات الشخصية (المشكلات السلوكية)، والتفكير الغير طبيعي (التفكير البطيء، غير قادر على التركيز)؛&nbsp;</p><p>&bull; تشنجات عضلية لا يمكن السيطرة عليها تؤثر على الرأس والجذع والأطراف، وصعوبة في السيطرة على الحركات، فرط الحراك (فرط النشاط)؛&nbsp;</p><p>&bull; التهاب البنكرياس؛&nbsp;</p><p>&bull; الفشل الكبدي والتهاب الكبد؛&nbsp;</p><p>&bull; طفح جلدي، والتي قد تشكل بثور ويبدو كالأهداف الصغيرة (البقع السوداء المركزية وتحيط بها منطقة اشحب، مع حلقة مظلمة حول الحافة) (حمامي&nbsp;عديدة الأشكال)، طفح جلدي على نطاق واسع مع ظهور بثور وتقشير الجلد، وخاصة حول الفم، الأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون)، وشكل أكثر شدة مما يتسبب في تقشير الجلد في أكثر من 30٪ من سطح الجسم (انحلال البشرة السمي).&nbsp;</p><p>اذا كان لديك أي آثار جانبية تحدث إلى طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير المدرجة في هذه النشرة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول ونظر الأطفال.&nbsp;</p><p>لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة بعد&nbsp;EXP. وتاريخ الإنتهاء يشير إلى أخر يوم فى الشهر المذكور.&nbsp;</p><p>هذا الدواء لا يتطلب أى ظروف تخزين خاصة.&nbsp;</p><p>لا&nbsp;يحفظ في درجة حرارة أعلى&nbsp;من&nbsp;30&nbsp;درجة مئوية.&nbsp;</p><p>يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الاعتبارات ستعمل على حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp; إن المادة الفعالة هي ليفيتيراسيتام&nbsp;</p><p>&nbsp;يحتوي كل قرص مغلف بطبقة رقيقة على 500 ملجم ليفيتيراسيتام.&nbsp;&nbsp;-&nbsp; المكونات الأخرى هى:&nbsp; كروسبوفيدون، بوفيدون، سيليكا غروية لامائية، ستيرات المغنيسيوم، بولي فينيل الكحول جزء. تحلل، ماكروغول 4000، تلك، وثاني أكسيد التيتانيوم&nbsp; (E171)،أكسيد الحديد الأصفر (E172) ، إنديجو كارمين (E12)&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص مغلفة بطبقة رقيقة&nbsp; 500 ملجم أقراص مغلفة بطبقة رقيقة:&nbsp; قرص بيضاوي، أصفر، 17.1&nbsp;&nbsp;X&nbsp;8.1 ملم مع وضع علامة &quot;L&quot; على جانب و &quot;500&quot; على الجانب الآخر.&nbsp; أحجام العبوة&nbsp; الشرائط: 20، 30، 50، 60، 100، 120 و 200 قرص مغلف بطبقة رقيقة.&nbsp; حاويات القرص: 30 و 100 و 200 قرص مغلف بطبقة رقيقة.&nbsp; لا يتم تسويق كل أحجام العبوات.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائية&nbsp;</p><p>مصنع الأدوية بالقصيم&nbsp;</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية&nbsp;</p><p>المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEVETAM 500 mg film-coated tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500 mg levetiracetam. 

For the full list of excipients, see section 6.1 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet [tablet]. 

     - Yellow color, oval, biconvex, film-coated tablet, debosed with "105" on one side  

        and plain on the other side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEVETAM is indicated as monotherapy in the treatment of partial onset seizures with or without secondary&nbsp;generalisation&nbsp;in adults and adolescents from 16 years of age with newly diagnosed epilepsy.&nbsp;</p><p>LEVETAM is indicated as adjunctive therapy&nbsp;</p><p>&bull; in the treatment of partial onset seizures with or without secondary&nbsp;generalisation&nbsp;in adults, adolescents, children and infants from 1 month of age with epilepsy.&nbsp;</p><p>&bull; in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.&nbsp;</p><p>&bull; in the treatment of primary&nbsp;generalised&nbsp;tonic-clonic&nbsp;seizures in adults and adolescents from 12 years of age with Idiopathic&nbsp;Generalised&nbsp;Epilepsy.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology&nbsp;</p><p>Monotherapy for adults and adolescents from 16 years of age&nbsp;</p><p>The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1,500 mg twice daily.&nbsp;</p><p>Add-on therapy for adults (&ge;18 years) and adolescents (12 to 17 years) weighing 50 kg or more&nbsp;</p><p>The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.&nbsp;</p><p>Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.&nbsp;</p><p>&nbsp;</p><p>Special populations&nbsp;</p><p>Elderly (65 years and older)&nbsp;</p><p>Adjustment of the dose is recommended in elderly patients with compromised renal function (see &ldquo;Renal impairment&rdquo; below).&nbsp;</p><p>Renal impairment&nbsp;</p><p>The daily dose must be&nbsp;individualised&nbsp;according to renal function.&nbsp;</p><p>For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The&nbsp;CLcr&nbsp;in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="499" height="170" vspace="0" hspace="0" border="0" style="width:499px;height:170px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Dosing adjustment for adult and&nbsp;adolescents&nbsp;patients weighing more than 50 kg with impaired renal function:&nbsp;</p><table border="1"><tbody><tr><td><p>Group&nbsp;</p></td><td><p>Creatinine clearance (ml/min/1.73m2)&nbsp;</p></td><td><p>Dose and frequency&nbsp;</p></td></tr><tr><td><p>Normal&nbsp;</p></td><td><p>&gt; 80&nbsp;</p></td><td><p>500 to 1,500 mg twice daily&nbsp;</p></td></tr><tr><td><p>Mild&nbsp;</p></td><td><p>50-79&nbsp;</p></td><td><p>500 to 1,000 mg twice daily&nbsp;</p></td></tr><tr><td><p>Moderate&nbsp;</p></td><td><p>30-49&nbsp;</p></td><td><p>250 to 750 mg twice daily&nbsp;</p></td></tr><tr><td><p>Severe&nbsp;</p></td><td><p>&lt; 30&nbsp;</p></td><td><p>250 to 500 mg twice daily&nbsp;</p></td></tr><tr><td><p>End-stage renal disease patients undergoing dialysis (1)&nbsp;</p></td><td><p>-&nbsp;</p></td><td><p>500 to 1,000 mg once daily (2)&nbsp;</p></td></tr></tbody></table><p>(1)&nbsp;A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.&nbsp;</p><p>&nbsp;(2)&nbsp;Following dialysis, a 250 to 500 mg supplemental dose is recommended.&nbsp;</p><p>For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.&nbsp;</p><p>The&nbsp;CLcr&nbsp;in ml/min/1.73 m2&nbsp;may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="384" height="82" vspace="0" hspace="0" border="0" style="width:384px;height:82px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Ks= 0.45 in Term infants to 1 year old;&nbsp;ks= 0.55 in Children to less than 13 years and in adolescent female;&nbsp;ks= 0.7 in&nbsp;adolescent&nbsp;male.&nbsp;</p><p>Dosing adjustment for infants, children and&nbsp;adolescents&nbsp;patients weighing less than 50 kg with impaired renal function&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1"><tbody><tr><td><p>Group&nbsp;</p></td><td><p>Creatinine clearance (ml/min/1.73 m2)&nbsp;</p></td><td><p>Dose and frequency&nbsp;(1)&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Infants 1 to less than 6 months&nbsp;</p></td><td><p>Infants 6 to 23 months, children and adolescents weighing less than 50 kg&nbsp;</p></td></tr><tr><td><p>Normal&nbsp;</p></td><td><p>&gt; 80&nbsp;</p></td><td><p>7 to&nbsp;21  mg/kg twice daily&nbsp;</p></td><td><p>10 to 30 mg/kg twice daily&nbsp;</p></td></tr><tr><td><p>Mild&nbsp;</p></td><td><p>50-79&nbsp;</p></td><td><p>7 to 14 mg/kg twice daily&nbsp;</p></td><td><p>10 to 20 mg/kg twice daily&nbsp;</p></td></tr><tr><td><p>Moderate&nbsp;</p></td><td><p>30-49&nbsp;</p></td><td><p>3.5 to 10.5 mg/kg twice daily&nbsp;</p></td><td><p>5 to 15 mg/kg twice daily&nbsp;</p></td></tr><tr><td><p>Severe&nbsp;</p></td><td><p>&lt; 30&nbsp;</p></td><td><p>3.5 to 7 mg/kg twice daily&nbsp;</p></td><td><p>5 to 10 mg/kg twice daily&nbsp;&nbsp;</p></td></tr><tr><td><p>End-stage renal disease patients&nbsp;</p><p>undergoing dialysis&nbsp;</p></td><td><p>--&nbsp;</p></td><td><p>7 to 14 mg/kg once daily&nbsp;(2) (4)&nbsp;</p></td><td><p>10 to 20 mg/kg once daily&nbsp;(3) (5)&nbsp;</p></td></tr></tbody></table><p>(1)&nbsp;An oral solution should be used for doses under 250 mg and for patients unable to swallow tablets.&nbsp;</p><p>(2)&nbsp;A 10.5 mg/kg loading dose is recommended on the first day of treatment with levetiracetam.&nbsp;</p><p>(3)&nbsp;A 15 mg/kg loading dose is recommended on the first day of treatment with levetiracetam.&nbsp;</p><p>(4)&nbsp;Following dialysis, a 3.5 to 7 mg/kg supplemental dose is recommended.&nbsp;</p><p>(5)&nbsp;Following dialysis, a 5 to 10 mg/kg supplemental dose is recommended.&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50 % reduction of the daily maintenance dose is recommended when&nbsp;the creatinine clearance is &lt; 60 ml/min/1.73 m2.&nbsp;</p><p>Paediatric&nbsp;population&nbsp;</p><p>The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.&nbsp;</p><p>The tablet formulation is not adapted for use in infants and children under the age of 6 years. An oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases an oral solution should be used.&nbsp;</p><p>Monotherapy&nbsp;</p><p>The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.&nbsp;</p><p>There are no data available.&nbsp;</p><p>Add-on therapy for infants aged from 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg&nbsp;</p><p>The initial therapeutic dose is 10 mg/kg twice daily.&nbsp;</p><p>Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.&nbsp;</p><p>Dose in children 50 kg or greater is the same as in adults.&nbsp;</p><p>Dose recommendations for infants from 6 months of age, children and adolescents:&nbsp;</p><table border="1"><tbody><tr><td><p>Weight&nbsp;</p></td><td><p>Starting dose:&nbsp;</p><p>10 mg/kg twice daily&nbsp;</p><p>&nbsp;</p></td><td><p>Maximum dose:&nbsp;</p><p>30 mg/kg twice daily&nbsp;</p><p>&nbsp;</p></td></tr><tr><td><p>6 kg&nbsp;(1)&nbsp;</p></td><td><p>60 mg twice daily&nbsp;</p></td><td><p>180 mg twice daily&nbsp;</p></td></tr><tr><td><p>10 kg&nbsp;(1)&nbsp;</p></td><td><p>100 mg twice daily&nbsp;</p></td><td><p>300 mg twice daily&nbsp;</p></td></tr><tr><td><p>15 kg&nbsp;(1)&nbsp;</p></td><td><p>150 mg twice daily&nbsp;</p></td><td><p>450 mg twice daily&nbsp;</p></td></tr><tr><td><p>20 kg&nbsp;(1)&nbsp;</p></td><td><p>200 mg twice daily&nbsp;</p></td><td><p>600 mg twice daily&nbsp;</p></td></tr><tr><td><p>25 kg&nbsp;</p></td><td><p>250 mg twice daily&nbsp;</p></td><td><p>750 mg twice daily&nbsp;</p></td></tr><tr><td><p>From 50 kg&nbsp;(2)&nbsp;&nbsp;</p></td><td><p>500 mg twice daily&nbsp;</p></td><td><p>1,500 mg twice daily&nbsp;</p></td></tr></tbody></table><p>(1)&nbsp;Children 25 kg or less should preferably start the treatment with an oral solution.&nbsp;</p><p>(2)&nbsp;Dose in children and adolescents 50 kg or more is the same as in adults.&nbsp;</p><p>Add-on therapy for infants aged from 1 month to less than 6 months&nbsp;</p><p>An oral solution is the formulation to use in infants.&nbsp;</p><p>Method of administration&nbsp;</p><p>The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. The daily dose is administered in two equally divided doses.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Discontinuation&nbsp;</p><p>In accordance with current clinical practice, if LEVETAM&nbsp; has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighing less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks).&nbsp;</p><p>Renal insufficiency&nbsp;</p><p>The administration of LEVETAM to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).&nbsp;</p><p>Suicide&nbsp;</p><p>Suicide, suicide attempt, suicidal ideation and&nbsp;behaviour&nbsp;have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and&nbsp;behaviour. The mechanism of this risk is not known.&nbsp;</p><p>Therefore, patients should be monitored for signs of depression and/or suicidal ideation and&nbsp;behaviours&nbsp;and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or&nbsp;behaviour&nbsp;emerge.&nbsp;</p><p>&nbsp;</p><p>Paediatric&nbsp;population&nbsp;</p><p>The tablet formulation is not adapted for use in infants and children under the age of 6 years.&nbsp;&nbsp;</p><p>Available data in children did not suggest&nbsp;impact&nbsp;on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.&nbsp;</p><p>The safety and efficacy of levetiracetam has not been thoroughly assessed in infants with epilepsy aged less than 1 year. Only 35 infants aged less than 1 year with partial onset seizures have been exposed in clinical studies of which only 13 were aged &lt; 6 months.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antiepileptic medicinal products&nbsp;</p><p>Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.&nbsp;</p><p>As in adults, there is no evidence of clinically significant medicinal product interactions in&nbsp;paediatric&nbsp;patients receiving up to 60 mg/kg/day levetiracetam.&nbsp;</p><p>A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.&nbsp;</p><p>Probenecid&nbsp;</p><p>Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low. It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite. The effect of levetiracetam on probenecid was not studied and the effect of levetiracetam on other actively secreted medicinal products,&nbsp;e.g.&nbsp;NSAIDs, sulfonamides and methotrexate, is unknown.&nbsp;</p><p>Oral contraceptives and other pharmacokinetics interactions&nbsp;</p><p>Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol&nbsp;and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.&nbsp;&nbsp;</p><p>Antacids&nbsp;</p><p>No data on the influence of antacids on the absorption of levetiracetam are available.&nbsp;</p><p>&nbsp;</p><p>Food and alcohol&nbsp;</p><p>The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.&nbsp;</p><p>No data on the interaction of levetiracetam with alcohol are available.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>Pregnancy category: C&nbsp;</p><p>There are no adequate data available from the use of levetiracetam in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for human is unknown.&nbsp;</p><p>LEVETAM is not recommended during pregnancy and in women of childbearing potential not using contraception unless clearly necessary.&nbsp;</p><p>As with other antiepileptic medicinal products, physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60 % of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured. Discontinuation of antiepileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the&nbsp;foetus.&nbsp;</p><p>Breastfeeding&nbsp;</p><p>Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the&nbsp;treatment should be weighed considering the importance of breastfeeding.&nbsp;</p><p>Fertility&nbsp;</p><p>No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.&nbsp;</p><p>Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks,&nbsp;e.g. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile&nbsp;</p><p>The adverse event profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. These data are supplemented with the use of levetiracetam in corresponding&nbsp;openlabel&nbsp;extension studies, as well as&nbsp;postmarketing&nbsp;experience. The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The safety profile of levetiracetam is generally similar across age groups (adult and&nbsp;paediatric&nbsp;patients) and across the approved epilepsy indications.&nbsp;</p><p>Tabulated list of adverse reactions&nbsp;</p><p>Adverse reactions reported in clinical studies (adults, adolescents, children and infants &gt;1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. The frequency is defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000).&nbsp;</p><table border="1"><tbody><tr><td><p>MedDRA SOC&nbsp;</p></td><td><p>Frequency category&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Very common&nbsp;</p></td><td><p>Common&nbsp;</p></td><td><p>Uncommon&nbsp;&nbsp;</p></td><td><p>Rare&nbsp;</p></td></tr><tr><td><p>Infections and infestations&nbsp;</p></td><td><p>Nasopharyngitis&nbsp;&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Infection&nbsp;</p></td></tr><tr><td><p>Blood and lymphatic system disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Thrombocytopenia, leukopenia&nbsp;</p></td><td><p>Pancytopenia,&nbsp;neutropenia&nbsp;</p></td></tr><tr><td><p>Metabolism and nutrition disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Anorexia&nbsp;</p></td><td><p>Weight decreased, weight increase&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Psychiatric disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Depression, hostility/ aggression, anxiety,&nbsp;&nbsp;<br />insomnia, nervousness/irritability&nbsp;</p></td><td><p>Suicide attempt, suicidal ideation,&nbsp;psychotic disorder, abnormal&nbsp;behaviour, hallucination, anger,&nbsp;confusional&nbsp;state&nbsp;,&nbsp;panic attack, affect lability/mood swings, agitation&nbsp;</p></td><td><p>Completed suicide, personality disorder, thinking abnormal&nbsp;</p></td></tr><tr><td><p>Nervous system disorders&nbsp;</p></td><td><p>Somnolence, headache&nbsp;</p></td><td><p>Convulsion, balance disorder, dizziness, lethargy, tremor&nbsp;</p></td><td><p>Amnesia, memory impairment, coordination abnormal/ataxia,&nbsp;paraesthesia, disturbance in attention&nbsp;</p></td><td><p>Choreoathetosis, dyskinesia, hyperkinesia&nbsp;</p></td></tr><tr><td><p>Eye disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Diplopia, vision blurred&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Ear and labyrinth disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Vertigo&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Cough&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Abdominal pain,&nbsp;diarrhoea, dyspepsia,&nbsp;vomiting, nausea&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Pancreatitis&nbsp;</p></td></tr><tr><td><p>Hepatobiliary disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Liver function test abnormal&nbsp;</p></td><td><p>Hepatic failure, hepatitis&nbsp;</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Rash&nbsp;</p></td><td><p>Alopecia, eczema, pruritus,&nbsp;&nbsp;</p></td><td><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme&nbsp;</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Muscular weakness, myalgia&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>General disorders and administration site conditions&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Asthenia/fatigue&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Injury, poisoning and procedural complications&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Injury&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Description of selected adverse reactions&nbsp;</p><p>The risk of anorexia is higher when topiramate is&nbsp;coadministered&nbsp;with levetiracetam. In several cases of alopecia, recovery was observed when levetiracetam was discontinued. Bone marrow suppression was identified in some of the cases of pancytopenia.&nbsp;</p><p>&nbsp;</p><p>Paediatric&nbsp;population&nbsp;</p><p>In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. Sixty (60) of these patients&nbsp;were treated with levetiracetam in placebo-controlled studies. In patients aged 416 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these&nbsp;paediatric&nbsp;age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam.&nbsp;</p><p>The adverse event profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in&nbsp;paediatric&nbsp;patients in&nbsp;placebocontrolled&nbsp;clinical studies were consistent with the safety profile of levetiracetam in adults except for&nbsp;behavioural&nbsp;and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal&nbsp;behaviour&nbsp;(common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.&nbsp;</p><p>A double-blind, placebo-controlled&nbsp;paediatric&nbsp;safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to&nbsp;behavioural&nbsp;and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive&nbsp;behaviour&nbsp;as measured in a&nbsp;standardised&nbsp;and systematic way using a validated instrument (CBCL &ndash; Achenbach Child&nbsp;Behaviour&nbsp;Checklist).&nbsp;However&nbsp;subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their&nbsp;behavioural&nbsp;and emotional functioning; in particular measures of aggressive&nbsp;behaviour&nbsp;were not worse than baseline.&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>To report any side effect(s):&nbsp;</p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)&nbsp;</p><p>o Fax: +966-11-205-7662&nbsp;</p><p>o&nbsp;Call NPC at +966-11-2038222,&nbsp;Exts: 2317-2356-2353-2354-2334-2340.&nbsp;</p><p>o Toll free phone: 8002490000&nbsp;</p><p>o E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p>o Website: www.sfda.gov.sa/npc&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms&nbsp;</p><p>Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses.&nbsp;</p><p>Management of&nbsp;overdose&nbsp;</p><p>After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis.&nbsp;</p><p>There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include&nbsp;haemodialysis. The&nbsp;dialyser&nbsp;extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14.&nbsp;</p><p>The active substance, levetiracetam, is a pyrrolidone derivative (Senantiomer&nbsp;of ethyl2oxo1pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.&nbsp;</p><p>Mechanism of action&nbsp;</p><p>The mechanism of action of levetiracetam still remains to be fully elucidated but appears to be different from the mechanisms of current antiepileptic medicinal products.&nbsp;In vitro&nbsp;and&nbsp;in vivo&nbsp;experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.&nbsp;</p><p>In vitro&nbsp;studies show that levetiracetam affects intraneuronal Ca2+&nbsp;levels by partial inhibition of&nbsp;Ntype&nbsp;Ca2+&nbsp;currents and by reducing the release of Ca2+&nbsp;from intraneuronal stores. In&nbsp;addition&nbsp;it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and &beta;carbolines. Furthermore, levetiracetam has been shown in&nbsp;in vitro&nbsp;studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.&nbsp;</p><p>Pharmacodynamic effects&nbsp;</p><p>Levetiracetam induces seizure protection in a broad range of animal models of partial and primary&nbsp;generalised&nbsp;seizures without having a pro-convulsant effect. The primary metabolite is inactive.&nbsp;</p><p>In man, an activity in both partial and&nbsp;generalised&nbsp;epilepsy conditions (epileptiform discharge/photoparoxysmal&nbsp;response) has confirmed the&nbsp;broad spectrum&nbsp;pharmacological profile of levetiracetam.&nbsp;</p><p>Clinical efficacy and safety&nbsp;</p><p>Adjunctive therapy in the treatment of partial onset seizures with or without secondary&nbsp;generalisation&nbsp;in adults, adolescents, children and infants from 1 month of age with epilepsy.&nbsp;</p><p>In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1,000 mg, 2,000 mg, or 3,000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1,000, 2,000 or 3,000 mg levetiracetam respectively and of 12.6 % for patients on placebo.&nbsp;</p><p>Paediatric&nbsp;population&nbsp;</p><p>&nbsp;</p><p>In&nbsp;paediatric&nbsp;patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).&nbsp;</p><p>44.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo had a 50 % or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure-free for at least 1 year.&nbsp;</p><p>In&nbsp;paediatric&nbsp;patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six month and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.&nbsp;</p><p>The primary measure of effectiveness was the responder rate (percent of patients with &ge; 50 %&nbsp;reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG. The efficacy analysis consisted of 109 patients who had at least 24 hours of video EEG in both baseline and evaluation periods. 43.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo were considered as responders. The results are consistent across age group. With continued long-term treatment, 8.6 % of the patients were seizure-free for at least 6 months and 7.8 % were seizure-free for at least 1 year.&nbsp;</p><p>Monotherapy in the treatment of partial onset seizures with or without secondary&nbsp;generalisation&nbsp;in patients from 16 years of age with newly diagnosed epilepsy.&nbsp;</p><p>Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, noninferiority comparison to&nbsp;carbamazepine controlled&nbsp;release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic&nbsp;seizures only. The patients were randomized to carbamazepine CR 400-1,200 mg/day or levetiracetam 1,000-3,000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.&nbsp;</p><p>Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 % (95 % CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6 % and 58.5 % of subjects on levetiracetam and on carbamazepine CR respectively).&nbsp;</p><p>In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).&nbsp;</p><p>Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.&nbsp;</p><p>&nbsp;</p><p>Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy.&nbsp;</p><p>In this study, levetiracetam, dose was 3,000 mg/day given in 2 divided doses.&nbsp;</p><p>58.3 % of the levetiracetam treated patients and 23.3 % of the patients on placebo had at least a 50 % reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year.&nbsp;</p><p>Adjunctive therapy in the treatment of primary&nbsp;generalised&nbsp;tonic-clonic&nbsp;seizures in adults and adolescents from 12 years of age with idiopathic&nbsp;generalised&nbsp;epilepsy.&nbsp;</p><p>Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic&nbsp;(PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, levetiracetam dose was 3,000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.&nbsp;</p><p>72.2 % of the levetiracetam treated patients and 45.2 % of the patients on placebo had a 50 % or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4 % of the patients were free of tonic-clonic&nbsp;seizures for at least 6 months and 31.5 % were free of tonic-clonic&nbsp;seizures for at least 1 year.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.&nbsp;</p><p>Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight.&nbsp;Therefore&nbsp;there is no need for plasma level monitoring of levetiracetam.&nbsp;</p><p>A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).&nbsp;</p><p>Adults and adolescents&nbsp;</p><p>Absorption&nbsp;</p><p>Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100 %.&nbsp;</p><p>Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. Steady-state is achieved after two days of a twice daily administration schedule.&nbsp;</p><p>Peak concentrations (Cmax) are typically 31 and 43 &mu;g/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.&nbsp;</p><p>The extent of absorption is dose-independent and is not altered by food.&nbsp;</p><p>Distribution&nbsp;</p><p>No tissue distribution data are available in humans.&nbsp;</p><p>Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (&lt; 10%).&nbsp;</p><p>The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.&nbsp;</p><p>Biotransformation&nbsp;</p><p>Levetiracetam is not extensively&nbsp;metabolised&nbsp;in humans. The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite,&nbsp;ucb&nbsp;L057, is not supported by liver cytochrome P450&nbsp;isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite&nbsp;ucb&nbsp;L057 is pharmacologically inactive.&nbsp;</p><p>Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose). Other unidentified components accounted only for 0.6 % of the dose.&nbsp;</p><p>No enantiomeric interconversion was evidenced&nbsp;in vivo&nbsp;for either levetiracetam or its primary metabolite.&nbsp;</p><p>In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450&nbsp;isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2),&nbsp;glucuronyl&nbsp;transferase (UGT1A1 AND UGT1A6]) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the&nbsp;in vitro&nbsp;glucuronidation of valproic acid.&nbsp;</p><p>In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and&nbsp;in vivo&nbsp;interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected&nbsp;in vivo. Therefore, the interaction of&nbsp;LEVETAM&nbsp; with&nbsp;other substances, or&nbsp;vice versa,&nbsp;is unlikely.&nbsp;</p><p>Elimination&nbsp;</p><p>The plasma half-life in adults was 7&plusmn;1 hours&nbsp;and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.&nbsp;&nbsp;</p><p>The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours). Excretion&nbsp;via&nbsp;faeces&nbsp;accounted for only 0.3 % of the dose.&nbsp;</p><p>The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.&nbsp;</p><p>&nbsp;</p><p>The renal clearance of levetiracetam and&nbsp;ucb&nbsp;L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. Levetiracetam elimination is correlated to creatinine clearance.&nbsp;</p><p>Elderly&nbsp;</p><p>In the elderly, the half-life is increased by about 40 % (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).&nbsp;</p><p>Renal impairment&nbsp;</p><p>The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of Levetiracetam Actavis, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).&nbsp;&nbsp;</p><p>In&nbsp;anuric&nbsp;end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.&nbsp;</p><p>The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session.&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2).&nbsp;</p><p>Paediatric&nbsp;population&nbsp;</p><p>Children (4 to 12 years)&nbsp;</p><p>Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.&nbsp;</p><p>Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours.&nbsp;The apparent body clearance was 1.1 ml/min/kg.&nbsp;</p><p>Infants and children (1 month to 4 years)&nbsp;</p><p>Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).&nbsp;</p><p>&nbsp;</p><p>In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution. Age also had an influence on both parameters. This effect was pronounced for the younger infants, and subsided as age increased, to become negligible around 4 years of age.&nbsp;</p><p>In both population pharmacokinetic analyses, there was about a 20 % increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing AED.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity.&nbsp;</p><p>Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.&nbsp;</p><p>No adverse effects on male or female fertility or reproduction performance were observed in rats at doses up to 1,800 mg/kg/day (x 6 the MRHD on a mg/m2&nbsp;or exposure basis) in parents and F1 generation.&nbsp;</p><p>Two embryofetal development (EFD) studies were performed in rats at 400, 1,200 and 3,600 mg/kg/day. At 3,600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in fetal weight associated with a marginal increase in skeletal variations/minor anomalies. There was no effect on&nbsp;embryomortality&nbsp;and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3,600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2&nbsp;basis) and 1,200 mg/kg/day for fetuses.&nbsp;&nbsp;</p><p>Four&nbsp;embryofoetal&nbsp;development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day. The dose level of 1,800 mg/kg/day induced a marked maternal toxicity and a decrease in&nbsp;foetal&nbsp;weight associated with increased incidence of&nbsp;foetuses&nbsp;with&nbsp;cardiovascular/skeletal anomalies. The NOAEL was &lt;200 mg/kg/day for the dams and 200 mg/kg/day for the&nbsp;foetuses&nbsp;(equal to the MRHD on a mg/m2&nbsp;basis).&nbsp;&nbsp;</p><p>A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1,800 mg/kg/day. The NOAEL was &ge; 1,800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m2&nbsp;basis).&nbsp;</p><p>Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6 &ndash; 17 the MRHD on a mg/m2&nbsp;basis).&nbsp;</p><p>Environmental Risk Assessment (ERA)&nbsp;</p><p>The use of&nbsp;LEVETAM&nbsp; in&nbsp;accordance with the product information is not likely to result in an unacceptable environmental impact (see section 6.6).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Crospovidon&nbsp;</p><p>Povidone&nbsp;</p><p>Silica colloidal anhydrous&nbsp;</p><p>Magnesium stearate&nbsp;</p><p>Polyvinyl alcohol &ndash; part. hydrolyzed&nbsp;</p><p>Macrogol 4000&nbsp;</p><p>Talc&nbsp;</p><p>Titanium dioxide (E171)&nbsp;</p><p>Indigo carmine (E132)&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.&nbsp;</p><p>Do not store above 30&deg; C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC/Aluminum Blister.&nbsp;</p><p>Pack size:&nbsp;</p><p>30 film-coated tablets.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO 

Al-Qassim Pharmaceutical Plant 

Saudi Arabia 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2019. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>